Cyclosporine A effectively inhibits graft‐versus‐host disease during development of Epstein‐Barr virus‐infected human B cell lymphoma in SCID mouse
Authors:
- 1 September 2003
- journal article
- Published by Wiley in Cancer Science
- Vol. 94 (9) , 796-801
Abstract
We previously constructed human peripheral blood lymphocyte (hu‐PBL)/severe combined immunodeficiency mouse (SCID) chimeras and induced human B‐cell lymphomas associated with Epstein‐Barr virus (EBV) in SCID mice. However, a number of SCID mice died of graft‐versus‐host disease (GVHD) during the early experimental course. The aim of this study was to test the efficacy of cyclosporine A (CSA) for prevention of GVHD and to define how CSA inhibits the occurrence of GVHD and the production of soluble interleukin (IL) 2 receptor (sIL‐2R) in hu‐PBL/SCID mice. No mouse died in the active EBV infection group with CSA administration, while 17 mice in three groups without CSA administration died of GVHD. Mortalities in these three groups were 55.56% (5/9), 30.43% (7/23), and 27.78% (5/18), and the medium life span was 17 days. Over the first 33 days after hu‐PBL transplantation, serum level of human sIL‐2R in hu‐PBL/SCID chimeras was stable in the active EBV infection plus CSA group, while sIL‐2R concentration gradually increased in the sera of mice with active EBV infection without CSA administration and peaked at 22 days. Thirty‐two mice developed tumors among the 43 surviving SCID mice. There was no significant difference of tumor incidence between the active EBV infection groups with CSA and without CSA administration (P>0.05). From their morphological and immunohistochemical features, as well as detection of human Alu‐sequence and EBV in tumor cells, these EBV‐induced tumors were identified as human B‐cell lymphomas. Thus, CSA can strikingly inhibit GVHD in hu‐PBL/SCID chimeras, and should therefore be effective to establish a stable SCID mouse model of human lymphoma associated with EBV. Treatment with CSA had no effect on the tumor incidence in hu‐PBL/SCID chimeras after active EBV infection. Accordingly, serum level of sIL‐2R is a valuable indicator of GVHD occurrence in hu‐PBL/SCID chimeras.Keywords
This publication has 23 references indexed in Scilit:
- Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)Bone Marrow Transplantation, 2003
- The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathyTransplantation, 2003
- Immunosuppressive drugs in islet xenotransplantation: a tool for gaining further insights in the mechanisms of the rejection processTransplantation, 2002
- Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugsClinical and Experimental Immunology, 2002
- CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic TransplantationBone Marrow Transplantation, 2002
- Advances in interleukin 2 receptor targeted treatmentAnnals of the Rheumatic Diseases, 2000
- Soluble Interleukin-2 Receptor Concentration As a Biochemical Indicator for Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow TransplantationJournal of Hematotherapy & Stem Cell Research, 2000
- Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft‐versus‐host diseaseBritish Journal of Haematology, 1999
- Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cellsImmunology, 1998
- Epstein-Barr Virus-Induced Human B-Cell Lymphoma Arising in HuPBL-SCID Chimeric Mice: Characterization and the Role of CD40 Stimulation in Their Treatment and PreventionPathobiology, 1995